Sign up to our newsletter Subscribe
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Sign up to our newsletter Subscribe
As more and more medicines come to market with multiple indications or the unrealised potential to treat multiple indications, the way we pay for those medicines becomes critical in making sure we can benefit from them. Indication-based pricing (IBP) permits price to vary according to indication and has been proposed to tackle this issue.
An error has occurred, please try again later.